Strategy for improving survival and reducing recurrence of HCV-related hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 19, Issue 37, 2013, Pages 6127-6130

  Ishikawa, Toru ^a  

^a Saiseikai Niigata Daini Hospital   (Japan)

Author keywords

Arterial chemotherapy; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Intrahepatic distant recurrence; Multicentric recurrence

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; DDPH; DOXORUBICIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG;

CHEMOEMBOLIZATION; DISEASE CLASSIFICATION; DRUG EFFICACY; EDITORIAL; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SURVIVAL;

ARTERIAL CHEMOTHERAPY; HEPATITIS C VIRUS; HEPATOCELLULAR CARCINOMA; INTERFERON; INTRAHEPATIC DISTANT RECURRENCE; MULTICENTRIC RECURRENCE;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; RECURRENCE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885615662     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i37.6127     Document Type: Editorial

References (23)

1. Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-Robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev Gastroenterol Hepatol 2009; 3: 353-367 [PMID: 19673623 DOI: 10.1586/egh.09.35]
2. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554 [PMID: 17133492 DOI: 10.1002/hep.21415]
3. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, Zheng SS, Sarin S, Hamid SS, Modawi SB, Fleig W, Fedail S, Thomson A, Khan A, Malfertheiner P, Lau G, Carillo FJ, Krabshuis J, Le Mair A. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010; 44: 239-245 [PMID: 20216082 DOI: 10.1097/MCG.0b013e3181d46ef2]
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/ NEJM199603143341104]
5. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]
6. Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012; 107: 569-77; quiz 578 [PMID: 22158026 DOI: 10.1038/ajg.2011.425]
7. Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003; 38: 200-207 [PMID: 12547409 DOI: 10.1016/S0168-8278(02)00360-4]
8. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]
9. Togo S, Tanaka K, Masui H, Matsuo K, Morioka D, Kurosawa H, Miura Y, Endo I, Sekido H, Shimada H. Usefulness of prophylactic transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Int Surg 2005; 90: 103-108 [PMID: 16119716]
10. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 17th Nationwide Followup Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691 [PMID: 17617112]
11. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 2012; 59: 529-532 [PMID: 22024226 DOI: 10.5754/hge10867]
12. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009; 44 Suppl 19: 119-121 [PMID: 19148805 DOI: 10.1007/s00535-008-2244-z]
13. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364 [PMID: 21829027 DOI: 10.1159/000327577]
14. Satake M, Uchida H, Arai Y, Anai H, Sakaguchi H, Nagata T, Yamane T, Kichikawa K, Osaki Y, Okazaki M, Higashihara H, Nakamura H, Osuga K, Nakao N, Hirota S. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 2008; 31: 756-761 [PMID: 18389187 DOI: 10.1007/s00270-007-9255-7]
15. Takayasu K, Arii S, Ikai I, Kudo M, Matsuyama Y, Kojiro M, Makuuchi M. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roentgenol 2010; 194: 830-837 [PMID: 20173167 DOI: 10.2214/AJR.09.3308]
16. Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatinlipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs 2011; 22: 277-282 [PMID: 21360850 DOI: 10.1097/CAD.0b013e328342231d]
17. Kasai K, Ushio A, Sawara K, Miyamoto Y, Kasai Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3437-3444 [PMID: 20632449]
18. Kaibori M, Tanigawa N, Matsui Y, Kwon AH, Sawada S, Kamiyama Y. Preoperative chemolipiodolization of the whole liver for hepatocellular carcinoma. Anticancer Res 2004; 24: 1929-1933 [PMID: 15274379]
19. Kaibori M, Tanigawa N, Kariya S, Ikeda H, Nakahashi Y, Hirohara J, Koreeda C, Seki T, Sawada S, Okazaki K, Kwon AH. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci 2012; 57: 1404-1412 [PMID: 22271410 DOI: 10.1007/s10620-012-2029-3]
20. Ishikawa T, Higuchi K, Kubota T, Seki K, Honma T, Yoshida T, Kamimura T. Prevention of intrahepatic distant recurrence by transcatheter arterial infusion chemotherapy with platinum agents for stage I/II hepatocellular carcinoma. Cancer 2011; 117: 4018-4025 [PMID: 21365625 DOI: 10.1002/ cncr.25989]
21. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
22. Ishikawa T, Imai M, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Kamimura T. Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and entericcoated tegafur/uracil: a pilot study. World J Gastroenterol 2007; 13: 5465-5470 [PMID: 17907289]
23. Ishikawa T. Future perspectives on the treatment of hepatocellular carcinoma with cisplatin. World J Hepatol 2009; 1: 8-16 [PMID: 21160960 DOI: 10.4254/wjh.v1.i1.8]